Armistice Capital’s NeuroSense Therapeutics Warrant NRSNW Stock Holding History

Armistice Capital’s Portfolio NRSNW Stock Details NRSNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-425,000	Closed	-$388K	–	168
2021 Q4	$388K	Buy	+425,000	New	+$379K	0.01%	133

Other funds holding NRSNW

EAM

Empery Asset Management New York $83M AUM

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

Armistice Capital's NRSNW Position: Q1 2022 in Review

Armistice Capital sold out of NeuroSense Therapeutics Warrant (NRSNW) in Q1 2022, closing a stake of 425,000 shares — an estimated $388K sold.

Armistice Capital first reported a position in NRSNW in Q4 2021 and held it in 1 quarter. The position peaked at $388K in Q4 2021. 4 funds tracked by Wall St. Rank hold NRSNW as of Q1 2022.

Armistice Capital reported no remaining NeuroSense Therapeutics Warrant position as of Q1 2022 after selling out during the quarter.
Armistice Capital sold 425,000 NeuroSense Therapeutics Warrant shares in Q1 2022, an estimated $388K.
Armistice Capital first reported a position in NeuroSense Therapeutics Warrant in Q4 2021 and held it in 1 quarter.
Armistice Capital's NeuroSense Therapeutics Warrant position peaked at $388K in Q4 2021.
4 funds tracked by Wall St. Rank held NeuroSense Therapeutics Warrant as of Q1 2022.

Based on Armistice Capital's 13F filing for Q1 2022, filed 16 May 2022.